Table 3.

Summary of NY-ESO-1 antibody titers, T-cell responses, SNPs, NY-ESO-1 expression, and clinical outcome

Humoral responseT cell responsesTLR SNP analysis
Study armaPIDAntibody titerCD4CD8TLR 7 rs179008TLR 8 rs3764880NY-ESO-1 expression in tumorClinical outcome
A008++NDAWD
A009+++++Deceased
A012+++NDNED
A016+++NDDeceased
A018+++NDResected-NED
A020++++Lost to follow-up
A022++NDNED
A025+++++NDDeceased
B007++NDDeceased
B010+++NED
B011++++++++Deceased
B013+++++++Resected-NED
B014++++NED
B015++NED
B017++++++Resected-NED
B019b+++++NED
B021++++NDResected-NED
B023b++++++++Deceased
B024++++NDResected-NED
B026b+++NDResected-NED

NY-ESO-1 antibody titers: 1–9,999: +; 10,000–99,999: ++; 100,000–249,000: +++; ≥250,000: ++++.

NY-ESO-1 expression in tumor: ND, not done due to insufficient tumor tissue; PID, patient identification number.

Latest clinical outcome: AWD, alive with disease; NED, no evidence of disease.

  • aArm A: patients receiving NY-ESO-1 protein, Montanide, and placebo gel; Arm B: patients receiving NY-ESO-1 protein, Montanide, and resiquimod gel.

  • bPrevaccine antibody response.